Navigation Links
Abatacept and infliximab improve clinical response over time in methotrexate-refractory RA patients
Date:6/13/2008

Paris, France, Friday 13 June 2008: New data presented today at EULAR 2008, the Annual Congress of the European League Against Rheumatism in Paris, France, show that over half of rheumatoid arthritis patients resistant to methotrexate monotherapy improved when either abatacept or infliximab were added to their methotrexate treatment regimen, with positive results sustained up to one year later.

The ATTEST (Abatacept or infliximab versus placebo, a Trial for Tolerability, Efficacy and Safety in Treating RA) trial compared abatacept (~10mg/kg), a selective T cell co-stimulation modulator, with infliximab (3mg/kg), a monoclonal antibody, plus methotrexate (as per each patient's usual dosage, mean dose 16.3-16.6mg) in 431 methotrexate-refractory patients, in a randomised, double-blind, placebo-controlled, 12-month study. Data analyses evaluated the proportion of patients who achieved a 20% improvement in symptoms (as defined by the American College of Rheumatology scale as an ACR20 response) at six months and went on to either improve, maintain or lose this score at twelve months. A similar analysis was conducted in relation to Low Disease Activity Score (LDAS) (DAS28 [CRP] ≤3.2).

ACR Response

Of those patients who achieved an ACR20 response at six months (32 abatacept [ABA] and 27 infliximab [IFX] patients), over a quarter of ABA and IFX patients went on to achieve a 50% improvement (ACR50) at one year (ABA 28.1%, IFX 29.6%). These ACR20 scores were maintained to one year in more ABA than INF patients (95% confidence interval, CI) with over half ABA patients sustained (ABA 59.4%, IFX 44.4%). Furthermore, half as many ABA patients lost their ACR20 score between six months and one year compared to IFX patients (ABA 12.5%, IFX 25.9%).

Low Disease Activity Score

In the LDAS analysis, it was shown that 24 ABA and 23 IFX patients achieved LDAS (but not remission) at six months. Of these patients, over a third ABA (41.7% [22.8, 63.1]) and a quarter IFX patients (28% [12.9, 49.6]) achieved remission at one year. A similar number of ABA (12.5% [3.3, 33.5]) and IFX patients (16% [5.3, 36.9]) retained LDAS to one year, whilst fewer ABA patients (45.8% [26.2, 66.9]) than IFX patients (56% [35.3, 75.0]) lost their LDAS score between six months and one year.

Lead researcher Dr Michael Schiff, of the University of Colorado, USA, commented: "Since RA is a chronic disease, long term treatment efficacy is crucial. Clinical rheumatologists and patients alike need to know the options for maintaining or even increasing treatment responses over time, especially with the growing problem of RA patients becoming refractory, or resistant, to existing treatments. Our study offers significant promise in showing that, where treatment with methotrexate as monotherapy is inadequate, both abatacept and infliximab provide an increasing magnitude of response in measures of RA disease activity, with abatacept yielding slightly higher results across some key ACR and LDAS scores."


'/>"/>

Contact: Rory Berrie / Camilla Dormer
eularpressoffice@uk.cohnwolfe.com
44-077-892-70392
European League Against Rheumatism
Source:Eurekalert

Related medicine news :

1. Infliximab scheduled treatment has proven to be an effective strategy in IBD patients
2. Vision restoration therapy shown to improve brain activity in brain injured patients
3. Broad-based group of physicians calls for improvement in stroke treatment
4. Frequent Prostate Screens Fail to Improve Aggressive Cancer Diagnoses
5. Pill box organizers increase HIV patients adherence and improve viral suppression
6. Treating depression may improve recovery of heart rate variability following coronary syndromes
7. Study Demonstrates Marteks Algal DHA Oil Improves Blood Triglyceride Lipid Levels
8. AWWA, National Association of Water and Sanitation of Mexico, Agree to Share Expertise and Resources for Improved Water Supply
9. Exercise and yoga improves quality of life in women with early-stage breast cancer
10. QI projects may -- or may not -- improve patient safety and outcomes
11. National Association for Sport and Physical Education Partners with S&S Worldwide to Help Improve Childrens Fitness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... An April 24th article on Yahoo! Beauty discusses ... with the help of a weight loss surgery. The woman, declaring “I will not hate ... been left following her dramatic weight loss. Dr. Feiz & Associates notes that, while it ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... its new partnership with the Home Care Association of America (HCAOA). This agreement ... Private Duty Accreditation services, as well as discounts on Accreditation University (AU) educational ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... to announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep physicians to ... since it streamlines the reporting process and provides a familiar interface that does ...
(Date:4/28/2017)... ... ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) announced today that ... as “stable.” At the same time, the ratings agency cautioned that the company’s rating ... “capital adequacy” thresholds required for its strong rating. , “Horizon is committed to being ...
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, Inc. announced today ... throughout the Northeast U.S. , GlycoMark is the only clinically available blood ... provides a clinically proven one- to two-week measure of hyperglycemic excursions, often related ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017  Cogentix Medical, Inc. (NASDAQ: ... providing the Urology, Uro/Gyn and Gynecology markets with ... Keswani has joined the Company as Senior Vice ... created position, Mr. Keswani will report directly to ... "Our organization is delighted that Ash has ...
(Date:4/20/2017)...  RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage ... unmet medical needs, today announced that it will ... development program, based on its proprietary self-delivering RNAi ... (SID) 76 th Annual Meeting.  The SID ... relevant to skin health and disease through education, ...
(Date:4/20/2017)... April 20, 2017  AbbVie (NYSE: ABBV), a ... (n=145/146) of chronic hepatitis C virus (HCV) infected ... 6 and compensated cirrhosis (Child-Pugh A) achieved sustained ... ) with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir ... seen following 12 weeks of G/P treatment without ...
Breaking Medicine Technology: